Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVATE early prophylaxis study for inhibitor prevention in previously untreated hemophilia A patients
2011-000410-18Phase 3Terminated
- Sponsor
- Baxter International Inc.
- Start
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Baxter International Inc. Primary endpoint: Incidence of inhibitor formation in severe and moderately severe hemophilia A within the first 50 exposure days to ADVATE. Started Mar 2011; status: terminated.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2011-000410-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000410-18.